Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus

Published:2014-01-17 Issue:3 Volume:74 Page:325-351
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

McCormack Paul L.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-013-0172-6.pdf

Reference134 articles.

1. World Health Organization. Diabetes: Fact sheet No. 312; 2013. http://www.who.int/mediacentre/factsheets/fs312/en/index.html . Accessed 28 Nov 2013.

2. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31–40.

3. Barnett AH. Complementing insulin therapy to achieve glycemic control. Adv Ther. 2013;30:557–76.

4. Parkes DG, Mace KF, Trautmann ME. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov. 2013;8(2):219–44.

5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus;Exploration of Drug Science;2024-04-03

2. The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats;Fundamental & Clinical Pharmacology;2023-12-27

3. In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases;European Journal of Pharmacology;2022-10

4. Beneficial Influence of Exendin-4 on Specific Organs and Mechanisms Favourable for the Elderly with Concomitant Obstructive Lung Diseases;Brain Sciences;2022-08-17

5. Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus;Frontiers in Endocrinology;2022-08-16